412 related articles for article (PubMed ID: 12133456)
21. Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L; Bertuzzi A; Nozza A; Siracusano L; Balzarotti M; Magagnoli M; Sarina B; Timofeeva I; Sinnone M; Grimoldi MG; Farè M; Santoro A
Bone Marrow Transplant; 2002 Aug; 30(4):207-14. PubMed ID: 12203136
[TBL] [Abstract][Full Text] [Related]
22. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies.
Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z
Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392
[TBL] [Abstract][Full Text] [Related]
23. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
24. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M;
Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656
[TBL] [Abstract][Full Text] [Related]
27. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
[TBL] [Abstract][Full Text] [Related]
28. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
Wu BY; Guo KY; Song CY; Yang ; Li D
Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
[TBL] [Abstract][Full Text] [Related]
29. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
30. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients.
Iravani M; Evazi MR; Mousavi SA; Shamshiri AR; Tavakoli M; Ashouri A; Samiee S; Chahardovali B; Alimoghaddam K; Ghaffari SH; Ghavamzadeh A
Bone Marrow Transplant; 2007 Jul; 40(2):105-10. PubMed ID: 17468775
[TBL] [Abstract][Full Text] [Related]
32. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
[TBL] [Abstract][Full Text] [Related]
33. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
[TBL] [Abstract][Full Text] [Related]
34. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Majolino I; Saglio G; Scimè R; Serra A; Cavallaro AM; Fiandaca T; Vasta S; Pampinella M; Catania P; Indovina A; Marcenò R; Santoro A
Bone Marrow Transplant; 1996 Apr; 17(4):555-60. PubMed ID: 8722354
[TBL] [Abstract][Full Text] [Related]
35. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
36. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
[TBL] [Abstract][Full Text] [Related]
37. [Clinical significance of formation and conversion of hematopoietic mixed chimerism in nonmyeloablative allogeneic stem cell transplantation].
Ai HS; Yu CL; Wang DH; Guo M; Qiao JH; Shi BF; Sun WJ; Zhang S; Sun QY; Yao B
Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):208-11. PubMed ID: 12812663
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic peripheral stem cell transplantation using positively selected CD34+ cells from HLA-mismatched donors.
Matsuda Y; Hara J; Osugi Y; Fujisaki H; Takai K; Ohta H; Nakanishi K; Tokimasa S; Miyoshi H; Tanaka-Taya K; Yamanishi K; Okada S
Bone Marrow Transplant; 1998 Feb; 21(4):355-60. PubMed ID: 9509968
[TBL] [Abstract][Full Text] [Related]
39. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
[TBL] [Abstract][Full Text] [Related]
40. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
